Cargando…

SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry

BACKGROUND: There is a lack of data on SARS-CoV-2 vaccination safety in children and young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). Current vaccination guidance is based on data from adults with RMDs or CYP without RMDs. OBJECTIVES: To describe the safety of SARS-COV-2 vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawson-Tovey, Saskia, Machado, Pedro M, Strangfeld, Anja, Mateus, Elsa, Gossec, Laure, Carmona, Loreto, Raffeiner, Bernd, Bulina, Inita, Clemente, Daniel, Zepa, Julija, Rodrigues, Ana M., Mariette, Xavier, Hyrich, Kimme L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Infections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344592/ https://www.ncbi.nlm.nih.gov/pubmed/35908834 http://dx.doi.org/10.1136/rmdopen-2022-002322

Ejemplares similares

P61 SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
por: Lawson-Tovey, Saskia, et al.
Publicado: (2022)

Tolérance de la vaccination contre le SRAS-CoV-2 chez les patients atteints de maladies rhumatologiques inflammatoires/auto-immunes : résultats du registre EULAR-COVAX chez 5121 patients
por: Mariette, X., et al.
Publicado: (2021)

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
por: Liew, Jean, et al.
Publicado: (2022)

Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
por: Gianfrancesco, Milena A, et al.
Publicado: (2020)

EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases
por: Najm, Aurélie, et al.
Publicado: (2019)

Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Eular Textbook on Rheumatic Diseases
por: Adwan, Marwan H.
Publicado: (2015)

Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives
por: Alunno, Alessia, et al.
Publicado: (2017)

Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider
por: Ritschl, Valentin, et al.
Publicado: (2020)

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
por: van der Heijde, Désirée, et al.
Publicado: (2015)

Rheumatic disease and COVID-19: epidemiology and outcomes
por: Hyrich, Kimme L., et al.
Publicado: (2020)

Recommendations for the content and conduct of European League Against Rheumatism (EULAR) musculoskeletal ultrasound courses
por: Naredo, E, et al.
Publicado: (2008)

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
por: Strangfeld, Anja, et al.
Publicado: (2021)

COVAX and the many meanings of sharing
por: Storeng, Katerini Tagmatarchi, et al.
Publicado: (2021)

Role of ultrasonography in the diagnosis of rheumatic diseases in light of ACR/EULAR guidelines
por: Płaza, Mateusz, et al.
Publicado: (2016)

Vaccine shortages prompt changes to COVAX strategy
por: Usher, Ann Danaiya
Publicado: (2021)

COVAX and equitable access to COVID-19 vaccines
por: Yoo, Katelyn J, et al.
Publicado: (2022)

Joint COVAX statement on the equal recognition of vaccines
Publicado: (2021)

COVAX: more than a beautiful idea
por: Berkley, Seth
Publicado: (2021)

COVAX – Time to reconsider the strategy and its target
por: Bell, David, et al.
Publicado: (2023)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology
por: Lauper, Kim, et al.
Publicado: (2021)

EULAR recommendations for intra-articular therapies
por: Uson, Jacqueline, et al.
Publicado: (2021)

The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register
por: Humphreys, Jennifer H, et al.
Publicado: (2013)

EULAR definition of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2021)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

OA31 Successes and challenges in harmonising 4 national Juvenile Idiopathic Arthritis cohorts: an example from CLUSTER consortium
por: Lawson-Tovey, Saskia, et al.
Publicado: (2022)

Covax announces new agreement, plans for first deliveries
Publicado: (2021)

Access to COVID-19 vaccines: looking beyond COVAX
por: The Lancet
Publicado: (2021)

Risky business: COVAX and the financialization of global vaccine equity
por: Stein, Felix
Publicado: (2021)

COVAX, vaccine donations and the politics of global vaccine inequity
por: de Bengy Puyvallée, Antoine, et al.
Publicado: (2022)

Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
por: Bosch, Philipp, et al.
Publicado: (2021)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
por: Kostine, Marie, et al.
Publicado: (2021)

Transitional care for rheumatic conditions in Europe: current clinical practice and available resources
por: Clemente, Daniel, et al.
Publicado: (2017)

Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases
por: Marques, Andréa, et al.
Publicado: (2022)

Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
Publicado: (2022)

Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
por: Burska, Agata, et al.
Publicado: (2023)

A beautiful idea: how COVAX has fallen short
por: Usher, Ann Danaiya
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_97um7mnfoul8qg074kk4765j6n